Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | IMVT |
---|---|---|
09:32 ET | 2139 | 28.13 |
09:34 ET | 300 | 28.305 |
09:36 ET | 500 | 28.3 |
09:38 ET | 4450 | 28.44 |
09:39 ET | 857 | 28.39 |
09:41 ET | 3500 | 28.405 |
09:43 ET | 300 | 28.38 |
09:45 ET | 2559 | 28.49 |
09:48 ET | 2780 | 28.455 |
09:52 ET | 1606 | 28.5 |
09:54 ET | 2228 | 28.44 |
09:56 ET | 1264 | 28.5 |
09:57 ET | 100 | 28.435 |
09:59 ET | 323 | 28.435 |
10:01 ET | 1600 | 28.505 |
10:03 ET | 2052 | 28.6 |
10:06 ET | 108988 | 28.58 |
10:08 ET | 4935 | 28.31 |
10:10 ET | 2657 | 28.275 |
10:12 ET | 1330 | 28.235 |
10:14 ET | 897 | 28.25 |
10:15 ET | 200 | 28.145 |
10:17 ET | 2929 | 28.28 |
10:19 ET | 3607 | 28.3 |
10:21 ET | 831 | 28.38 |
10:24 ET | 1841 | 28.32 |
10:26 ET | 1292 | 28.378 |
10:28 ET | 700 | 28.44 |
10:30 ET | 510 | 28.38 |
10:32 ET | 1000 | 28.31 |
10:33 ET | 500 | 28.31 |
10:35 ET | 19320 | 28.46 |
10:37 ET | 15834 | 28.46 |
10:39 ET | 1551 | 28.64 |
10:42 ET | 1000 | 28.62 |
10:44 ET | 1330 | 28.665 |
10:46 ET | 900 | 28.775 |
10:48 ET | 2053 | 28.68 |
10:50 ET | 4813 | 28.475 |
10:51 ET | 1307 | 28.41 |
10:53 ET | 1439 | 28.37 |
10:55 ET | 2300 | 28.34 |
10:57 ET | 2107 | 28.385 |
11:00 ET | 1300 | 28.34 |
11:02 ET | 1075 | 28.405 |
11:04 ET | 14148 | 28.5 |
11:06 ET | 12393 | 28.5 |
11:08 ET | 17628 | 28.48 |
11:09 ET | 4896 | 28.405 |
11:11 ET | 1300 | 28.425 |
11:13 ET | 1200 | 28.425 |
11:15 ET | 3066 | 28.44 |
11:18 ET | 1500 | 28.34 |
11:20 ET | 1692 | 28.315 |
11:22 ET | 1391 | 28.35 |
11:24 ET | 200 | 28.365 |
11:26 ET | 1182 | 28.28 |
11:27 ET | 2141 | 28.3675 |
11:29 ET | 1501 | 28.28 |
11:31 ET | 144 | 28.266 |
11:33 ET | 200 | 28.28 |
11:36 ET | 636 | 28.29 |
11:38 ET | 400 | 28.2075 |
11:40 ET | 979 | 28.21 |
11:42 ET | 1892 | 28.33 |
11:44 ET | 100 | 28.34 |
11:45 ET | 800 | 28.395 |
11:47 ET | 19930 | 28.35 |
11:49 ET | 200 | 28.355 |
11:51 ET | 900 | 28.35 |
11:56 ET | 1812 | 28.315 |
11:58 ET | 200 | 28.29 |
12:00 ET | 900 | 28.36 |
12:02 ET | 100 | 28.335 |
12:03 ET | 563 | 28.37 |
12:05 ET | 700 | 28.39 |
12:07 ET | 500 | 28.4 |
12:09 ET | 200 | 28.34 |
12:14 ET | 500 | 28.325 |
12:16 ET | 600 | 28.4 |
12:18 ET | 100 | 28.42 |
12:20 ET | 100 | 28.405 |
12:21 ET | 100 | 28.37 |
12:23 ET | 200 | 28.4 |
12:27 ET | 2176 | 28.28 |
12:30 ET | 2715 | 28.27 |
12:32 ET | 109 | 28.25 |
12:34 ET | 1966 | 28.18 |
12:36 ET | 800 | 28.23 |
12:38 ET | 300 | 28.25 |
12:41 ET | 600 | 28.13 |
12:43 ET | 28038 | 28.24 |
12:45 ET | 600 | 28.18 |
12:48 ET | 1309 | 28.16 |
12:50 ET | 288 | 28.2 |
12:52 ET | 326 | 28.19 |
12:54 ET | 1100 | 28.19 |
12:56 ET | 2250 | 28.25 |
12:57 ET | 528 | 28.21 |
12:59 ET | 1616 | 28.21 |
01:01 ET | 900 | 28.17 |
01:03 ET | 200 | 28.18 |
01:06 ET | 700 | 28.2 |
01:08 ET | 200 | 28.16 |
01:10 ET | 300 | 28.18 |
01:12 ET | 100 | 28.18 |
01:14 ET | 600 | 28.12 |
01:15 ET | 800 | 28.08 |
01:17 ET | 8699 | 28.085 |
01:19 ET | 8348 | 28.15 |
01:21 ET | 1960 | 28.12 |
01:24 ET | 1166 | 28.13 |
01:26 ET | 300 | 28.08 |
01:28 ET | 300 | 28.1 |
01:32 ET | 500 | 28.15 |
01:33 ET | 2200 | 28.15 |
01:35 ET | 500 | 28.15 |
01:37 ET | 2764 | 28.15 |
01:39 ET | 1754 | 28.165 |
01:42 ET | 700 | 28.17 |
01:44 ET | 811 | 28.165 |
01:46 ET | 2100 | 28.285 |
01:48 ET | 1500 | 28.255 |
01:51 ET | 752 | 28.27 |
01:53 ET | 300 | 28.27 |
01:55 ET | 300 | 28.27 |
01:57 ET | 1156 | 28.3 |
02:00 ET | 200 | 28.315 |
02:02 ET | 999 | 28.32 |
02:04 ET | 100 | 28.3001 |
02:06 ET | 400 | 28.31 |
02:08 ET | 775 | 28.3276 |
02:09 ET | 1219 | 28.29 |
02:11 ET | 639 | 28.305 |
02:15 ET | 795 | 28.28 |
02:18 ET | 1535 | 28.33 |
02:20 ET | 547 | 28.265 |
02:24 ET | 659 | 28.27 |
02:26 ET | 200 | 28.31 |
02:27 ET | 6984 | 28.43 |
02:31 ET | 400 | 28.43 |
02:33 ET | 1050 | 28.47 |
02:36 ET | 900 | 28.47 |
02:38 ET | 4716 | 28.575 |
02:40 ET | 699 | 28.565 |
02:44 ET | 700 | 28.57 |
02:45 ET | 5424 | 28.59 |
02:47 ET | 600 | 28.585 |
02:49 ET | 2122 | 28.605 |
02:51 ET | 1320 | 28.605 |
02:54 ET | 1820 | 28.58 |
02:56 ET | 131 | 28.6 |
02:58 ET | 1229 | 28.64 |
03:00 ET | 900 | 28.585 |
03:02 ET | 100 | 28.58 |
03:03 ET | 460 | 28.57 |
03:05 ET | 3620 | 28.585 |
03:07 ET | 900 | 28.58 |
03:09 ET | 700 | 28.62 |
03:12 ET | 446 | 28.63 |
03:14 ET | 100 | 28.6 |
03:16 ET | 1192 | 28.5938 |
03:18 ET | 1566 | 28.56 |
03:20 ET | 1994 | 28.52 |
03:21 ET | 2756 | 28.49 |
03:23 ET | 3483 | 28.37 |
03:25 ET | 1319 | 28.39 |
03:27 ET | 833 | 28.39 |
03:30 ET | 3395 | 28.48 |
03:32 ET | 1900 | 28.405 |
03:34 ET | 1000 | 28.413 |
03:36 ET | 700 | 28.41 |
03:38 ET | 2965 | 28.4 |
03:39 ET | 1456 | 28.44 |
03:41 ET | 1100 | 28.44 |
03:43 ET | 873 | 28.43 |
03:45 ET | 1406 | 28.421 |
03:48 ET | 2420 | 28.44 |
03:50 ET | 2950 | 28.47 |
03:52 ET | 5218 | 28.44 |
03:54 ET | 3012 | 28.475 |
03:56 ET | 7289 | 28.47 |
03:57 ET | 4655 | 28.47 |
03:59 ET | 149977 | 28.45 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Immunovant Inc | 4.2B | -14.8x | --- |
Crinetics Pharmaceuticals Inc | 4.1B | -13.8x | --- |
Madrigal Pharmaceuticals Inc | 4.6B | -8.2x | --- |
Biohaven Ltd | 4.7B | -5.3x | --- |
Dyne Therapeutics Inc | 3.6B | -9.7x | --- |
BridgeBio Pharma Inc | 4.8B | -9.4x | --- |
Immunovant, Inc. is a clinical-stage immunology company. The Company is focused on developing treatments for patients with autoimmune diseases. Its product pipeline includes batoclimab and IMVT-1402, both of which are novel, fully human monoclonal antibodies that target the neonatal fragment crystallizable receptor (FcRn). Batoclimab is a subcutaneous injection with dosing. Batoclimab is observed to reduce immunoglobulin G (IgG) antibodies that cause inflammation and disease. Its product candidate, batoclimab, is dosed in small volumes and with a 27-gauge needle. It is developing batoclimab for myasthenia gravis (MG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP) and Graves’ disease (GD). Its lead product candidate IMVT-1402 has also been observed to reduce IgG antibody levels in a Phase I clinical trial conducted in healthy adults. IMVT-1402 is a fully human monoclonal antibody that inhibits FcRn.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $4.2B |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 146.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.71 |
EPS | $-1.92 |
Book Value | $4.24 |
P/E Ratio | -14.8x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.